China-based 3D Medicines has entered into a strategic partnership with compatriot firm Denfo Medical Group, focusing on the research and development (R&D) and commercialization of novel cancer therapies. The collaboration will also cover cancer chroniclization management and novel drug services. Denfo Medical will leverage its interconnected, digitalized, and intelligent online platforms, combined with offline brick-and-mortar medical institutions, to develop online-to-offline (O2O) solutions aimed at enhancing the accessibility, safety, and cost-effectiveness of new special drugs in collaboration with 3D Medicines. Financial details of the partnership were not disclosed.
3D Medicines’ Pipeline and Key Assets
3D Medicines has a robust pipeline of 12 novel cancer therapies, with eight currently in clinical or commercialization stages. Among these, envafolimab (KN035), the world’s first PD-L1 single-domain antibody and human IgG1 Fc fusion protein capable of subcutaneous injection, has been approved for marketing in China. Additionally, the in-licensed polypeptide tumor vaccine 3D189 and GAS6/AXL inhibitor 3D229 have entered global Phase III clinical studies. The company’s in-house developed multi-targeted kinase inhibitor 3D011 is also under clinical development.
Denfo Medical’s Comprehensive Services
Denfo Medical provides full-life-cycle oncology medical services to patients, covering accurate pre-diagnosis screening and triage, application of new and special tumor drugs and technologies during diagnosis and perioperative support, and post-diagnosis oncology rehabilitation. The partnership with 3D Medicines aims to integrate these services with innovative cancer therapies, enhancing the overall patient experience and outcomes.-Fineline Info & Tech
